000			01939 a2200529 4500
005			20250517065126.0
264		0	_c20161107
008			201611s 0 0 eng d
022			_a1949-2553
024	7		_a10.18632/oncotarget.6378 _2doi
040			_aNLM _beng _cNLM
100	1		_aMayr, Christian
245	0	0	_aThe BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. _h[electronic resource]
260			_bOncotarget _cJan 2016
300			_a745-58 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAntineoplastic Agents _xpharmacology
650	0	4	_aBiliary Tract Neoplasms _xgenetics
650	0	4	_aCell Line, Tumor
650	0	4	_aCell Proliferation _xdrug effects
650	0	4	_aCell Survival _xdrug effects
650	0	4	_aCisplatin _xpharmacology
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Synergism
650	0	4	_aFlow Cytometry
650	0	4	_aG1 Phase Cell Cycle Checkpoints _xdrug effects
650	0	4	_aGene Expression Regulation, Neoplastic _xdrug effects
650	0	4	_aHeterocyclic Compounds, 2-Ring _xpharmacology
650	0	4	_aHumans
650	0	4	_aImmunohistochemistry
650	0	4	_aNeoplastic Stem Cells _xdrug effects
650	0	4	_aPolycomb Repressive Complex 1 _xantagonists & inhibitors
650	0	4	_aReverse Transcriptase Polymerase Chain Reaction
650	0	4	_aThiazoles _xpharmacology
700	1		_aWagner, Andrej
700	1		_aLoeffelberger, Magdalena
700	1		_aBruckner, Daniela
700	1		_aJakab, Martin
700	1		_aBerr, Frieder
700	1		_aDi Fazio, Pietro
700	1		_aOcker, Matthias
700	1		_aNeureiter, Daniel
700	1		_aPichler, Martin
700	1		_aKiesslich, Tobias
773	0		_tOncotarget _gvol. 7 _gno. 1 _gp. 745-58
856	4	0	_uhttps://doi.org/10.18632/oncotarget.6378 _zAvailable from publisher's website
999			_c25501610 _d25501610